Seoul, South Korea

Bum-Joon Kim

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Jeju-do, KR (2010)
  • Seoul, KR (2001 - 2022)

Company Filing History:


Years Active: 2001-2022

Loading Chart...
Loading Chart...
9 patents (USPTO):

Title: Innovations and Contributions of Inventor Bum-Joon Kim

Introduction

Bum-Joon Kim is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of vaccines and cancer immunotherapy. With a total of 9 patents to his name, his work has the potential to impact public health and cancer treatment.

Latest Patents

One of his latest patents is titled "Recombinant BCG expressing HIV-1 p24 using pMyong2 vector system and use thereof." This invention provides a recombinant BCG that employs a pMyong2 vector system to express HIV-1 p24, which can be utilized as an HIV-1 vaccine. The rBCG-pMyong2-p24 was found to induce the upregulation of HIV-1 p24 gag expression in rBCG and infected antigen-presenting cells (APC). It also improved p24-specific immune responses in vaccinated mice compared to rBCG-pAL-p24 in a pAL5000 derived vector system. Furthermore, rBCG-pMyong2-p24 exhibited a higher p24-specific antibody production level than rSmeg-pMyong2-p24 in the same vector system. This recombinant BCG is expected to elicit enhanced immune responses to HIV-1 infection in mouse model systems, making it a promising candidate for a prime vaccine in the heterologous prime-boost vaccination strategy against HIV-1 infection.

Another significant patent focuses on cancer immunotherapy. This invention relates to an anti-cancer regulatory response and immunotherapy that mediates cancer cytotoxicity through natural killer cells or T cells. It inhibits the activation of cancer cytotoxicity regulatory T cells of macrophages or dendritic cells, thereby inducing an immune response that inhibits tumor formation. This innovation holds promise as a cancer immunotherapeutic agent.

Career Highlights

Bum-Joon Kim has worked with esteemed institutions such as Seoul National University and Korea University Industrial & Academic Collaboration Foundation. His research and innovations have garnered attention in the scientific community, contributing to advancements in vaccine development and cancer treatment.

Collaborations

He has collaborated with notable colleagues, including Dong-Jin Byun and Jung-Geun Jhin, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Bum-Joon Kim

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…